Environmental and genetic factors can contribute to lung cancer, which develops as a result of cells growing out of control in the lungs.
Lung cancer is the
In recent years, screening for genetic mutations in cancerous lung tumors has become a crucial step in the diagnosis and treatment of lung cancer.
Experts who study genetic mutations implicated in lung cancer note that environmental and hereditary risk factors play a role.
In the United States, only
The Environmental Protection Agency (EPA) estimates that radon, the second most common cause of lung cancer, is responsible for the deaths of approximately 21,000 people each year, of whom approximately 2,900 have never smoked.
Other environmental factors associated with lung cancer include exposure to:
- outdoor and indoor air pollution
- heavy metals
- industrial emissions
- radiotherapy to the chest
Inherited DNA mutations increase the risk of certain types of cancer and may play a role in lung cancer.
The most common form of lung cancer in non-smokers is adenocarcinoma, which researchers have linked to ALK and EGFR mutations. For example, in a 2017 study, rates of ALK and EGFR mutations were higher in participants who had never smoked than in current smokers.
The ACS explains that experts do not believe that inherited genetic mutations alone cause many lung cancers. The genetic mutations that play a role in lung cancer are more likely to be those that people acquire during their lifetime.
Dr. Osita Onugha is a thoracic surgeon and assistant professor of thoracic surgery at the Saint John’s Cancer Institute at Providence Saint John’s Health Center in Santa Monica, California.
“Genetics play a role, but we don’t know exactly what kind of role at this point,” Dr. Onugha said. Medical News Today.
“We don’t have genetic screening [of healthy individuals] as is the case, for example, with breast cancer. For a patient with BRCA mutations, we know there is an increased risk of breast cancer and other cancers. We don’t have the same corollary with lung cancer and inherited genetic mutations,” he continued.
“That’s what we know right now. Ten years from now, we can say that a certain mutation means you have a particular risk of lung cancer,” Dr Onugha said.
“There is a combination of environmental and occupational exposure and genetics. That’s why some heavy smokers don’t get lung cancer, and others who smoke lightly do,” he concluded.
Dr. John Maurice is a thoracic surgeon and lung cancer specialist at the Cancer Prevention and Treatment Center at Providence St. Joseph’s Hospital in California.
“There’s definitely a family trait in lung cancer that we haven’t sifted through enough yet to understand these genes,” Dr. Maurice said. DTM.
“A person with lung cancer having a relative with lung cancer is quite common. Sometimes you can identify something there. There is a weakness in the gene repair mechanism, or the gene has a feature that facilitates mutations compared to others with a more robust repair mechanism,” he said.
“We don’t really understand how all the factors combine to produce cancer,” added Dr. Maurice.
Second-hand smoke is a known risk factor. Dr Onugha explained that the problem is that there is no way to quantify a person’s exposure to second-hand smoke.
There may also be a link between occupational exposure of parents or caregivers and the risk of lung cancer in children, as a review article in Translational research in lung cancer discuss. However, the exact roles of various genetic, environmental and occupational exposures in an individual are difficult to determine.
- 20 to 25% of non-small lung cancers (NSCLC) involve changes in the kras uncomfortable
- 10 to 20% involve the EGFR uncomfortable
- 5% involve the ALK uncomfortable
Other biomarkers associated with lung cancer include:
A 2020 research found that EGFR mutations are more common in non-smokers with lung cancer than in smokers with the disease. Other common genetic mutations in non-smokers with NSCLC are ALK and kras.
The authors of a 2017 retrospective study concluded that lung cancer in non-smokers is understudied. They also noted that the prevalence of lung cancer among non-smokers has increased.
“We started detecting the first genetic abnormalities associated with lung cancer about 15 years ago with EGFR mutations,” said Dr. Maurice. “Every person and every tumor has a different set of mutations, and they sometimes change over time.”
Dr. Onugha explained that experts’ discussion of cancer and genetics usually refers to factors that cause a certain family pattern.
“In the case of lung cancer, in general, we talk about tumor biology. We call these tumor mutations biomarkers. They are not hereditary. Biomarkers tell us how aggressive a tumor is and whether it can be treated with a particular drug,” he explained.
“Smokers and non-smokers may have different mutations. Treatment is now personalized based on your tumor biology,” Dr. Onugha noted.
“We’re talking about an area that has gone wild with developments,” said Dr Maurice.
“Gene sequencing took a long time. Now you can verify thousands of genes in minutes. We are moving at a breakneck pace. There are so many new developments that trials are competing for patients,” he added.
“We have treatments that did not exist 5 years ago. We are not going to do the same thing in 5 or 10 years. This is an evolving field,” stressed Dr. Maurice.
“As we identify more mutations, we can develop treatments to target them,” Dr Onugha said. “We have significantly improved the way we treat lung cancer patients. The future treatment is very bright and will have a huge impact on the survival of many lung cancer patients.
Heredity may play a role in the development of lung cancer. However, most cases of lung cancer are not linked to inherited genetic mutations. Lung cancer tumors are usually associated with acquired genetic mutations.
After a diagnosis of lung cancer, doctors will check the tumor for mutations that promote cancer growth. Biomarkers have paved the way for personalized treatment of lung cancer, and this area of research is advancing rapidly.
Smoking remains the main risk factor for developing lung cancer.